Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Manufacturing & supply

Lantern Pharma loses its CEO while moving two lung and breast cancer trials forward

Panna Sharma has resigned as chief executive of the oncology developer, which also raised about $4.0m and recorded a $2.0m accrual for a proposed consultant settlement.

18 Nov 2026 · Lantern Pharma Inc. LTRN · Company news

Lantern Pharma's chief executive has stepped down just as the company pushes two cancer studies into new phases and tops up its funds. Panna Sharma has resigned, and chief financial officer David Margrave will serve as interim CEO. The details came with the company's third-quarter 2026 update on 18 November. The information available does not explain why Sharma left or say when a permanent successor might be named.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Lantern Pharma Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Manufacturing & supplyAll →